101 related articles for article (PubMed ID: 8452012)
1. Inhibition of head and neck tumor cell colony growth by lymphokine activated killer cells.
Kumazawa H; Kita J; Sai S; Tachikawa T; Hori Y; Yamazaki N; Yamashita T; Kumazawa T; Kawamoto K; Koldovsky P
Acta Otolaryngol Suppl; 1993; 500():138-41. PubMed ID: 8452012
[TBL] [Abstract][Full Text] [Related]
2. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
[TBL] [Abstract][Full Text] [Related]
3. First place--Resident Clinical Science Award 1990. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck.
Strasnick B; Lagos N; Lichtenstein A; Mickel RA
Otolaryngol Head Neck Surg; 1990 Oct; 103(4):537-49. PubMed ID: 2123311
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells.
Dullens HF; Wind JC; Maas RA; Bernsen MR; Vulto IM; Rademakers LH; Den Otter W
Int Immunol; 1991 Oct; 3(10):959-64. PubMed ID: 1756146
[TBL] [Abstract][Full Text] [Related]
5. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
Burkey BB; Omann GM; Wolf GT
Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
[TBL] [Abstract][Full Text] [Related]
6. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lymphocyte function by head and neck carcinoma cell line soluble factors.
Bailet JW; Lichtenstein A; Chen G; Mickel RA
Arch Otolaryngol Head Neck Surg; 1997 Aug; 123(8):855-62. PubMed ID: 9260552
[TBL] [Abstract][Full Text] [Related]
8. Production of lymphokine-activated lymphocytes. Lysis of human head and neck squamous cell carcinoma cell lines.
Alessi DM; Hutcherson RW; Mickel RA
Arch Otolaryngol Head Neck Surg; 1989 Jun; 115(6):725-30. PubMed ID: 2785809
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
[TBL] [Abstract][Full Text] [Related]
10. [Establishing three dimensional tumors in vitro and the reaction of the lymphokine-activated killer cells (LAK) to the three dimensional tumors].
Kumazawa H; Koldovsky P; Kürten C; Hess M; Tujikawa S; Vosteen KH
Auris Nasus Larynx; 1991; 18(3):235-69. PubMed ID: 1799331
[TBL] [Abstract][Full Text] [Related]
11. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.
Clayman GL; Taylor DL; Liu FJ; Lavedan P; Savage HE; Schantz SP
Laryngoscope; 1993 Mar; 103(3):299-307. PubMed ID: 7680086
[TBL] [Abstract][Full Text] [Related]
12. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer.
Bugis SP; Lotzová E; Savage HE; Hester JP; Racz T; Sacks PG; Schantz SP
Cancer Immunol Immunother; 1990; 31(3):176-81. PubMed ID: 2337906
[TBL] [Abstract][Full Text] [Related]
14. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
[TBL] [Abstract][Full Text] [Related]
16. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2.
Sacchi M; Vitolo D; Sedlmayr P; Rabinowich H; Johnson JT; Herberman RB; Whiteside TL
Int J Cancer; 1991 Mar; 47(5):784-91. PubMed ID: 2004859
[TBL] [Abstract][Full Text] [Related]
17. Effect of lymphokine-activated killer cells on head and neck tumours in nude mouse model.
Kumazawa H; Koldovsky P; Kürten C; Vosteen KH
Acta Otolaryngol; 1989; 108(3-4):317-24. PubMed ID: 2816347
[TBL] [Abstract][Full Text] [Related]
18. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation of the induction phase of lymphokine-activated killer activity by acute phase proteins.
Clayman GL; Liu FJ; Taylor DL; Savage HE; Lavedan P; Buchsbaum RM; Trujillo JM; Schantz SP
Otolaryngol Head Neck Surg; 1991 Jul; 105(1):26-34. PubMed ID: 1715542
[TBL] [Abstract][Full Text] [Related]
20. [Induction of cytotoxic activity from regional lymph node lymphocytes in head and neck malignant tumor].
Yoda J
Nihon Jibiinkoka Gakkai Kaiho; 1992 May; 95(5):748-58. PubMed ID: 1619515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
